Analyst Ratings For Bioverativ (NASDAQ:BIVV)
Today, Argus reiterated its Buy rating on Bioverativ (NASDAQ:BIVV).
Some recent analyst ratings include
- 1/24/2018-Argus Reiterated Rating of Buy .
- 1/24/2018-Credit Suisse Group Reiterated Rating of Neutral.
- 1/23/2018-Raymond James Financial was Downgraded by analysts at Raymond James Financial from a “Strong-Buy ” rating to a ” Hold” rating.
- 1/23/2018-Morgan Stanley Upgrade from a “Underweight ” rating to a ” Equal Weight” rating.
- 1/22/2018-Jefferies Group was Downgraded by analysts at Jefferies Group from a “Buy ” rating to a ” Hold” rating.
- 1/22/2018-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Overweight ” rating to a ” Neutral” rating.
- On 8/9/2017 Brian S Posner, Director, bought 1,000 with an average share price of $59.19 per share and the total transaction amounting to $59,190.00.
- On 8/7/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $59.70 per share and the total transaction amounting to $119,400.00.
- On 6/28/2017 Diantha Duvall, Insider, sold 818 with an average share price of $60.47 per share and the total transaction amounting to $49,464.46.
- On 5/30/2017 Alexander J Denner, Director, bought 90,000 with an average share price of $55.93 per share and the total transaction amounting to $5,033,700.00.
- On 5/26/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $57.76 per share and the total transaction amounting to $115,520.00.
- On 5/24/2017 Brian S Posner, Director, bought 2,000 with an average share price of $53.86 per share and the total transaction amounting to $107,720.00.
Recent Trading Activity for Bioverativ (NASDAQ:BIVV)
Shares of Bioverativ closed the previous trading session at 103.27 up +0.11 0.11% with 102.87000274658203 shares trading hands.